by Kyle | Jul 12, 2023 | Press Release
Leading Diagnostic Healthcare Company Also Announces Over 50 Initial Clinic Commitments for Its Full Diagnostic Assay Platform SAN DIEGO, TBD DATE, 2022 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an...
by Kyle | May 23, 2023 | Press Release
Leading Diagnostic Healthcare Company Selects Accomplished Operations Executive to Spearhead Growth of Diagnostic Assays Manufacturing SAN DIEGO, CA, May 23, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM...
by Kyle | Apr 11, 2023 | Press Release
Leading Diagnostic Healthcare Company Begins Manufacturing of Ocular Immunoglobulin (IgE), Lactoferrin Tests to Fulfill Orders From Commercialization Partner SAN DIEGO, CA, April 11, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — AXIM Biotechnologies,...
by Kyle | Mar 14, 2023 | Press Release
Leading Diagnostic Healthcare Company Announces Provisional Patent Filing on Proprietary Use of Materials for Ophthalmological Test Strip Manufacturing SAN DIEGO, TBD DATE, 2022 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM”...
by Kyle | Jan 17, 2023 | Press Release
Diagnostic Healthcare Solutions Company Developing New Test Designed to Measure Neutralizing Antibodies of Deadly Opioid Fentanyl SAN DIEGO, TBD DATE, 2022 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an...
by Kyle | Jan 9, 2023 | Press Release
Summary: In 2022, AXIM® finalized optimization of its R&D and manufacturing infrastructure to be used in its diagnostic program AXIM will continue to generate revenue from its two FDA-cleared dry eye disease (DED) diagnostic tests through commercialization partner...
